

# Tuberculosis profile: Japan

Population 2021: 125 million

## Estimates of TB burden\*, 2021

	Number	(Rate per 100 000 population)
Total TB incidence	13 000 (11 000-15 000)	11 (9.1-12)
HIV-positive TB incidence	70 (25-140)	0.06 (0.02-0.11)
MDR/RR-TB incidence**	550 (0-1 300)	0.44 (0-1.1)
HIV-negative TB mortality	3 200 (3 000-3 400)	2.6 (2.4-2.7)
HIV-positive TB mortality	16 (5-32)	0.01 (0-0.03)

## Estimated proportion of TB cases with MDR/RR-TB\*, 2021

New cases	3.1% (0.54-10)
Previously treated cases	18% (1.8-54)

## Universal health coverage and social protection\*

TB treatment coverage (notified/estimated incidence), 2021	87% (75-100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2021	26% (22-30)

## TB case notifications, 2021

Total new and relapse	11 519
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	7.4%
- % pulmonary	73%
- % bacteriologically confirmed <sup>^</sup>	87%
- % children aged 0-14 years	1%
- % women (aged ≥15 years)	41%
- % men (aged ≥15 years)	58%
Total cases notified	11 519

## TB/HIV care in new and relapse TB patients, 2021

	Number	(%)
Patients with known HIV status who are HIV-positive	30	3.5%
- on antiretroviral therapy		

## Drug-resistant TB care\*\*, 2021

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases <sup>^</sup>	62%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases <sup>^</sup>	60%
Laboratory-confirmed cases - MDR/RR-TB <sup>^^</sup>	
Patients started on treatment - MDR/RR-TB <sup>^^^</sup>	
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB <sup>^^</sup>	
Patients started on treatment - pre-XDR-TB or XDR-TB <sup>^^^</sup>	
MDR/RR-TB cases tested for resistance to any fluoroquinolone	

## Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2020	65%	12 586
Previously treated cases, excluding relapse, registered in 2020		
HIV-positive TB cases registered in 2020	52%	31
MDR/RR-TB cases started on second-line treatment in 2019	57%	49
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2019		

## TB preventive treatment, 2021

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	36% (27-56)

\* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

\*\* RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone


<sup>^</sup> Calculated for pulmonary cases only

<sup>^^</sup> Includes cases with unknown previous TB treatment history

<sup>^^^</sup> Includes patients diagnosed before 2021 and patients who were not laboratory-confirmed


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)




## HIV-negative TB mortality

(Rate per 100 000 population per year)



## Incidence, Notified cases by age group and sex, 2021

(Number)



## Cases attributable to five risk factors, 2021

(Number)

